Cancer Research Meeting Calendar  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 59, 5112-5118, October 1, 1999]
© 1999 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nijjar, T.
Right arrow Articles by Yaswen, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nijjar, T.
Right arrow Articles by Yaswen, P.
[Cancer Research 59, 5112-5118, October 15, 1999]
© 1999 American Association for Cancer Research


Advances in Brief

p57KIP2 Expression and Loss of Heterozygosity during Immortal Conversion of Cultured Human Mammary Epithelial Cells1

Tarlochan Nijjar, Don Wigington, James C. Garbe, Andreas Waha, Martha R. Stampfer and Paul Yaswen2

Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720 [T. N., D. W., J. C. G., M. R. S., P. Y.], and Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, California 92093 [A. W.]

We have uncovered a novel role for the cyclin-dependent kinase inhibitor, p57KIP2, during the immortalization of cultured human mammary epithelial cells (HMECs). HMECs immortalized after chemical carcinogen exposure initially expressed little or no telomerase activity, and their telomeres continued to shorten with passage. Cell populations whose mean terminal restriction fragment (TRF) length declined to <=3 kb exhibited slow heterogeneous growth and contained many nonproliferative cells. These conditionally immortal HMEC cultures accumulated large quantities of p57 protein. With continued passage, the conditionally immortal cell populations very gradually converted to a fully immortal phenotype of good uniform growth, expression of high levels of telomerase activity, and stabilization of telomere length. The fully immortal HMECs that grew well did not accumulate p57 in G0 or during the cell cycle. DNA and RNA analysis of mass populations and individual subclones of conditionally immortal HMEC line 184A1 showed that continued growth of conditionally immortal cells with critically short telomeres was repeatedly accompanied by loss of the expressed p57 allele and transient expression of the allele imprinted previously. Conditionally immortal 184A1 with mean TRF >3 kb, infected with retroviruses containing the p57 gene, exhibited premature slow heterogeneous growth. Conversely, exogenous expression of human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, in 184A1 with mean TRF >3 kb prevented both the slow heterogeneous growth phase and accumulation of p57 in cycling populations. These data indicate that in HMECs that have overcome replicative senescence, p57 may provide an additional barrier against indefinite proliferation. Overcoming p57-mediated growth inhibition in these cells may be crucial for acquisition of the unlimited growth potential thought to be critical for malignant progression.




This article has been cited by other articles:


Home page
Cancer Res.Home page
R. J. Jin, Y. Lho, Y. Wang, M. Ao, M. P. Revelo, S. W. Hayward, M. L. Wills, S. K. Logan, P. Zhang, and R. J. Matusik
Down-regulation of p57Kip2 Induces Prostate Cancer in the Mouse
Cancer Res., May 15, 2008; 68(10): 3601 - 3608.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Li, Z. H. Meng, A. Sayeed, R. Shalaby, B.-M. Ljung, and S. H. Dairkee
Genome-wide Allelotyping of a New in Vitro Model System Reveals Early Events in Breast Cancer Progression
Cancer Res., October 15, 2002; 62(20): 5980 - 5987.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. W. Foster, A. R. Frost, P. McKie-Bell, C.-Y. Lin, J. A. Engler, W. E. Grizzle, and J. M. Ruppert
Increase of GKLF Messenger RNA and Protein Expression during Progression of Breast Cancer
Cancer Res., November 1, 2000; 60(22): 6488 - 6495.
[Abstract] [Full Text]


Home page
Am. J. Pathol.Home page
A. Tsugu, K. Sakai, P. B. Dirks, S. Jung, R. Weksberg, Y.-L. Fei, S. Mondal, S. Ivanchuk, C. Ackerley, P. A. Hamel, et al.
Expression of p57KIP2 Potently Blocks the Growth of Human Astrocytomas and Induces Cell Senescence
Am. J. Pathol., September 1, 2000; 157(3): 919 - 932.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. R. Stampfer, J. Garbe, G. Levine, S. Lichtsteiner, A. P. Vasserot, and P. Yaswen
Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells
PNAS, April 10, 2001; 98(8): 4498 - 4503.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.